Seres Therapeutics Inc
$ 8.65
6.00%
24 Feb - close price
- Market Cap 78,252,000 USD
- Current Price $ 8.65
- High / Low $ 9.00 / 8.21
- Stock P/E 9.83
- Book Value 4.99
- EPS 0.88
- Next Earning Report 2026-03-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.40 %
- ROE 0.16 %
- 52 Week High 29.98
- 52 Week Low 6.53
About
Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$21.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-03-03 | 2024-10-31 | 2024-08-13 | 2024-05-08 | 2024-03-05 | 2023-11-02 | 2023-08-08 | 2023-05-09 | 2023-03-07 |
| Reported EPS | 0.94 | -2.27 | -2.2375 | -0.11 | -0.33 | -0.22 | -0.27 | -0.32 | -0.37 | 0.36 | -0.57 | -0.54 |
| Estimated EPS | -0.0397 | -0.09 | 1.9701 | -0.1993 | -0.002 | -0.27 | -0.34 | -0.5 | -0.5 | 0.53 | -0.55 | -0.46 |
| Surprise | 0.9797 | -2.18 | -4.2076 | 0.0893 | -0.328 | 0.05 | 0.07 | 0.18 | 0.13 | -0.17 | -0.02 | -0.08 |
| Surprise Percentage | 2467.7582% | -2422.2222% | -213.5729% | 44.8068% | -16400% | 18.5185% | 20.5882% | 36% | 26% | -32.0755% | -3.6364% | -17.3913% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -2.39 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MCRB
2026-02-21 18:20:05
The pharmaceutical industry is showing increased interest in microbiome-based therapies following two recent FDA approvals for treatments targeting Clostridioides difficile (C. diff). These therapies, including Ferring Pharmaceuticals’ Rebyota and Seres Therapeutics’ Vowst, highlight the potential of rebalancing the body's microscopic organisms to treat various conditions beyond the gut, such as neurological disorders, inflammatory diseases, and even cancer. While the field is still emerging and considered risky, larger pharma companies and numerous biotech firms are investing in research and development to explore the broad therapeutic applications of microbiome modulation.
2026-02-21 14:00:50
The global gut microbiota market is projected to reach US$3,600.1 million by 2032, growing at a CAGR of 22.50% from US$579.5 million in 2023. This growth is driven by increasing consumer awareness of digestive wellness, advancements in microbiome sequencing, and the potential impact of gut microbiota on conditions like metabolic diseases, allergies, and mental health. The digestive health segment is expected to continue dominating, while research into the gut-brain axis presents significant opportunities for market expansion.
2026-02-20 22:51:10
The global live biotherapeutic products and microbiome CDMO market was valued at USD 55.19 million in 2024 and is projected to reach USD 1,075.98 million by 2033, growing at a CAGR of 39.10%. This growth is driven by increasing awareness of microbiome-based therapies, advancements in microbial engineering and AI-driven manufacturing, and supportive regulatory frameworks. North America currently dominates the market, while Asia-Pacific is expected to be the fastest-growing region.
2026-02-14 07:27:54
Wall Street Zen downgraded Seres Therapeutics (NASDAQ:MCRB) from a "hold" to a "sell" rating, with Weiss Ratings reissuing a "sell (d)" rating. The stock's consensus rating is now "Reduce" with a target price of $14.33, significantly higher than its opening price of $8.47. Despite the lowered ratings, institutional investors maintain a substantial stake, with several firms recently increasing or establishing positions in the biotechnology company.
2026-02-12 17:58:28
Seres Therapeutics, Inc. has announced strategic adjustments to extend its corporate operating cycle, including a cost optimization plan. The company plans to streamline its organizational structure and reduce its global workforce by approximately 30%. This move is intended to lower operating expenses and secure a longer funding cycle for its core R&D projects.
2026-02-12 15:57:22
Cambridge biotech Seres Therapeutics has halted work on its lead drug program, SER-155, and initiated layoffs due to a cash crunch. The company's current cash runway is projected to extend only through the third quarter without additional investment. This move impacts the clinical trial for SER-155, which was in development.
